Salix Pharmaceuticals Given New $127.00 Price Target at Mizuho (SLXP)
Research analysts at Mizuho increased their price target on shares of Salix Pharmaceuticals (NASDAQ:SLXP) to $127.00 in a report released on Friday, AnalystRatings.Net reports. Mizuho’s target price points to a potential upside of 31.70% from the company’s current price.
In other Salix Pharmaceuticals news, Director Alonzo Thomas D sold 12,050 shares of Salix Pharmaceuticals stock on the open market in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $91.83, for a total transaction of $1,106,551.50. Following the transaction, the director now directly owns 97,974 shares in the company, valued at approximately $8,996,952. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Several other analysts have also recently commented on the stock. Analysts at Brean Capital raised their price target on shares of Salix Pharmaceuticals from $90.00 to $108.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at UBS AG raised their price target on shares of Salix Pharmaceuticals from $68.00 to $94.00 in a research note to investors on Friday, January 10th. They now have a “neutral” rating on the stock. Finally, analysts at Merrill Lynch downgraded shares of Salix Pharmaceuticals to an “underperform” rating in a research note to investors on Tuesday, January 7th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $85.50.
Salix Pharmaceuticals (NASDAQ:SLXP) opened at 96.43 on Friday. Salix Pharmaceuticals has a one year low of $45.82 and a one year high of $97.90. The stock has a 50-day moving average of $88.31 and a 200-day moving average of $75.78. The company has a market cap of $6.065 billion and a price-to-earnings ratio of 56.63.
Salix Pharmaceuticals (NASDAQ:SLXP) last released its earnings data on Thursday, November 7th. The company reported $0.89 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.86 by $0.03. The company had revenue of $238.20 million for the quarter, compared to the consensus estimate of $239.70 million. During the same quarter last year, the company posted $0.95 earnings per share. Salix Pharmaceuticals’s revenue was up 28.7% compared to the same quarter last year. On average, analysts predict that Salix Pharmaceuticals will post $3.22 earnings per share for the current fiscal year.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.